Golimumab improves work productivity in patients suffering from moderate to severe ulcerative colitis: results of a prospective study over 24 months

Table 3 Concomitant diseases, extraintestinal manifestations and concomitant medication at baseline

	mITT (n = 282)
Patients with concomitant disease	127 (45.0)
Patients with EIMs of UC^a	31 (11.0)
Joint	24 (8.5)
Other	13 (4.6)
Patients extraintestinal concomitant disease associated with UC^a	5 (1.8)
Gall stone	3 (1.1)
Thromboembolic complications	2 (0.7)
Kidney stone	1 (0.4)
Common other concomitant diseases^a
Hypertension	28 (10.2)
Depression	9 (3.2)
Asthma	7 (2.5)
Osteoporosis	7 (2.5)
Other	23 (8.2)
Concomitant medication^a
No	85 (30.1)
Yes	197 (69.9)
Aminosylicylates	117 (41.5)
Corticosteroids	68 (24.1)
Immunosuppressives	39 (13.8)
Analgesics	15 (5.3)
Loperamid	7 (2.5)
Other^b	86 (30.5)

Data are shown as n (%)
^aMultiple answers were possible. mITT: modified intention to treat analysis set. EIM: extraintestinal manifestations
^bOther drugs mainly comprised antihypertensive drugs, antidiuretic agents, antidepressants, supplements, antidiabetics, oral contraceptives and non-steroidal anti-inflammatory drugs

ISSN: 1471-230X